Showing 6621-6630 of 7172 results for "".
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (
- Alphaeon Begins Phase III Study For Its Neurotoxin, Evosyalhttps://practicaldermatology.com/news/alphaeon-begins-phase-iii-study-for-its-neurotoxin-evosyal/2459018/The FDA agreed to Alphaeon® Corporations’s protocol for its Phase III clinical study of Evosyal™ to treat glabellar lines. Alphaeon acquired the exclusive US and certain international distribution rights to Evosyal, a botulinum toxin type A neuromodulator, as part of it
- Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-lynne-bulger-as-vice-president-medical-affairs/2459022/Cipher Pharmaceuticals Inc. appointed Lynne Bulger as Vice President, Medical and Clinical Affairs to lead the Company's clinical development and medical affairs efforts for current and new pipeline products. Ms. Bulger has 27 years of experience in drug development in the pharmaceuti
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its an
- XTRAC Offering Rebate for Excimer Laser Treatmentshttps://practicaldermatology.com/news/xtrac-offers-coupon-for-vitiligo-treatments/2459029/PhotoMedex is offering a limited-time rebate for patients treated with the XTRAC Excimer Laser from January 1 through March 31, 2015. The rebate is worth up to $100 per treatment and can be used to offset the costs of insurance deduc
- LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDAhttps://practicaldermatology.com/news/leo-pharma-submits-nda-for-aerosol-foam-for-psoriasis-to-fda/2459033/LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed w
- Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002https://practicaldermatology.com/news/revance-launches-phase-2-belmont-study/2459035/Specialty biopharmaceutical company Revance Therapeutics, Inc. has initiated the BELMONT trial, a Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and
- Alcohol Intake Not Linked to Early BCChttps://practicaldermatology.com/news/alcohol-intake-not-linked-to-early-bcc/2459036/Despite some trends suggesting that high alcohol use and high UV exposure may be associated with risk for early onset BCC in women, there is no statistically significant association between lifetime alcohol intake and early-onset BCC overall or in women only, new data from the
- FDA Approves Galderma's Soolantra to Treat Rosaceahttps://practicaldermatology.com/news/fda-approves-galdermas-soolantra-for-rosacea/2459038/The FDA approved Galderma’s Soolantra (ivermectin) Cream 1% for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. R Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are norma
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim